Delonix Bioworks Doses First Participant in DX-104 Trial
SHANGHAI, China, July 13, 2026 Delonix Bioworks, a clinical-stage biotechnology company specializing in genetically engineered bacterial vaccines, has announced...
Infectious Diseases
Advertisement
Saol Therapeutics Resubmits NDA for SL1009 in PDCD
ROSWELL, Ga., DUBLIN, Ireland & HAMILTON, Bermuda, July 7, 2026 Saol Therapeutics has announced the resubmission of its New...
Lakewood-Amedex Backs PASTEUR Act to Fight AMR Crisis
SARASOTA, Fla., July 7, 2026 Lakewood-Amedex Biotherapeutics has announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial...
Evaxion to Present EVX-V1 CMV Vaccine Preclinical Data
COPENHAGEN, Denmark, July 1, 2026 Evaxion A/S announced that it will present new preclinical data for its investigational cytomegalovirus...
Visby Medical Receives FDA Clearance for First Multi-Virus Home PCR
SAN JOSE, California, July 2, 2026 Visby Medical has received U.S. Food and Drug Administration (FDA) clearance for the...
Advertisements
PleoPharma Launches Phase 3 Trial for Cannabis Withdrawal
PHOENIXVILLE, Pa., June 20, 2026 PleoPharma, Inc. has announced the dosing of the first patient in CAN-004, its pivotal...
New Gates Foundation Grant Fuels Replicate’s Fight Against Tuberculosis
SAN DIEGO, Calif., June 20, 2026 Replicate Bioscience has secured a $3 million research grant from the Gates Foundation...
Moderna Gains FDA Panel Support for mRNA-1010 Flu Vaccine
CAMBRIDGE, Mass., June 20, 2026 Moderna, Inc. announced a major regulatory milestone for its investigational seasonal influenza vaccine mRNA-1010...
Merck’s CAPVAXIVE Wins FDA Approval for High-Risk Children
RAHWAY, N.J., June 18, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has approved an expanded...
Acurx Pharmaceuticals Showcases DNA pol IIIC Antibiotic Breakthrough
STATEN ISLAND, N.Y., June 16, 2026 Acurx Pharmaceuticals has announced the presentation of new scientific findings from its ongoing...
Advertisement
